Covered recipient · General Payments record
LAWRENCE GERVASI
Allopathic & Osteopathic Physicians Urology
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
Saved only in this browser. No account or alerts.
General Payments · PY2021 · Entire year
$104,760.68
177 records · 0 disputed
“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”
— Centers for Medicare & Medicaid Services, Open Payments
A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.
These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
How these totals are calculated
- This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Methodology & Data — sourcing, labeling, and limitations.
Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗
By nature of payment
PY2021 · entire year · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $86,279.00 | 33 |
| Consulting Fee | $8,285.50 | 4 |
| Travel and Lodging | $7,671.25 | 24 |
| Food and Beverage | $2,326.04 | 111 |
| Education | $198.89 | 5 |
By paying entity
PY2021 · entire year · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| Astellas Pharma US Inc | $61,051.69 | 55 |
| Janssen Biotech, Inc. | $14,617.43 | 17 |
| Myovant Sciences Inc. | $12,403.75 | 18 |
| Bayer HealthCare Pharmaceuticals Inc. | $9,720.09 | 17 |
| Exelixis Inc. | $1,980.00 | 1 |
| Janssen Scientific Affairs, LLC | $1,857.50 | 2 |
| GENZYME CORPORATION | $1,808.00 | 1 |
| TOLMAR Pharmaceuticals, Inc. | $296.88 | 10 |
| UROGEN PHARMA, INC. | $180.33 | 4 |
| Dendreon Pharmaceuticals LLC | $133.68 | 8 |
| AstraZeneca Pharmaceuticals LP | $122.11 | 9 |
| Blue Earth Diagnostics Limited | $90.21 | 4 |
| Teleflex LLC | $85.42 | 5 |
| Rochester Medical Corporation | $46.37 | 1 |
| AbbVie Inc. | $39.29 | 3 |
| Amgen Inc. | $38.89 | 2 |
| ConvaTec Inc. | $37.03 | 2 |
| COLOPLAST CORP | $36.45 | 3 |
| Allergan, Inc. | $32.52 | 2 |
| Merck Sharp & Dohme Corporation | $32.28 | 2 |
| Antares Pharma, Inc. | $32.04 | 2 |
| PFIZER INC. | $31.84 | 3 |
| Clarus Therapeutics Inc. | $31.37 | 2 |
| Progenics Pharmaceuticals, Inc. | $27.16 | 2 |
| Clovis Oncology, Inc. | $16.13 | 1 |
| DENTSPLY IH Inc. | $12.22 | 1 |
Page 3 of 4; records 101–150 of 177 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.
IndustryPayments · General Payments
LAWRENCE GERVASI
NPI 1265400592 · CMS profile ID 328763
Allopathic & Osteopathic Physicians / Urology
MIDDLEBURG HEIGHTS, OH
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types
Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00
Page 3 of 4; records 101–150 of 177 matching records. This page contains 50 records (maximum 50), not the full filtered export.
Filtered page: https://industrypayments.org/provider/npi-1265400592?year=2021&recipient=provider&page=3#records-h
CMS source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202
Cite these filtered records
The citation includes this program year, filters, data edition, and page of results.
- Plain
- LAWRENCE GERVASI, NPI 1265400592, CMS profile ID 328763. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 4; records 101–150 of 177 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1265400592?year=2021&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
- APA 7
- IndustryPayments. (2026). LAWRENCE GERVASI, NPI 1265400592, CMS profile ID 328763. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 4; records 101–150 of 177 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1265400592?year=2021&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
- Bluebook
- LAWRENCE GERVASI, NPI 1265400592, CMS profile ID 328763, IndustryPayments, General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 3 of 4; records 101–150 of 177 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202. https://industrypayments.org/provider/npi-1265400592?year=2021&recipient=provider&page=3#records-h.
Centers for Medicare & Medicaid Services, Open Payments
Citation formats are provided for reference; check the requirements of your publication.
Payment records · PY2021
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
General Payments · PY2021 · Physicians and non-physician practitioners · CMS publication 2026-06-30
177 matching records · $104,760.68 reported total · 0 disputed
Nature of payment: All payment types
Records imported here (UTC).
CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.
Showing records 101–150 of 177.
| Paying entity | Amount | Date | Nature of payment | Dispute status | Publication flags | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|---|
| Astellas Pharma US Inc | $4,870.00 | 07/11/2021 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 821333829 | CMS |
| Astellas Pharma US Inc | $229.09 | 07/11/2021 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 821333835 | CMS |
| Astellas Pharma US Inc | $27.97 | 07/11/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 821333841 | CMS |
| Astellas Pharma US Inc | $184.50 | 07/11/2021 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 821333847 | CMS |
| Blue Earth Diagnostics Limited | $21.44 | 07/08/2021 | Food and Beverage | No dispute reported | Delay: No Change: CHANGED | 06/30/2026 | 844624071 | CMS |
| AstraZeneca Pharmaceuticals LP | $13.77 | 07/07/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 829366101 | CMS |
| UROGEN PHARMA, INC. | $11.63 | 06/28/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 826677621 | CMS |
| Janssen Biotech, Inc. | $4,100.00 | 06/25/2021 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 788046483 | CMS |
| AbbVie Inc. | $14.31 | 06/24/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 794580125 | CMS |
| Astellas Pharma US Inc | $2,090.00 | 06/24/2021 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 821333819 | CMS |
| TOLMAR Pharmaceuticals, Inc. | $18.32 | 06/23/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 836496785 | CMS |
| Janssen Biotech, Inc. | $4.57 | 06/22/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 788046497 | CMS |
| Astellas Pharma US Inc | $21.03 | 06/14/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 821333811 | CMS |
| AstraZeneca Pharmaceuticals LP | $13.77 | 06/10/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 829612249 | CMS |
| Janssen Biotech, Inc. | $103.76 | 06/10/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 788046479 | CMS |
| Janssen Biotech, Inc. | $801.00 | 06/10/2021 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 788046481 | CMS |
| Astellas Pharma US Inc | $2,090.00 | 06/09/2021 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 821333807 | CMS |
| Myovant Sciences Inc. | $1,300.00 | 06/09/2021 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 834955459 | CMS |
| Bayer HealthCare Pharmaceuticals Inc. | $16.56 | 06/03/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 789162291 | CMS |
| Astellas Pharma US Inc | $2,090.00 | 06/02/2021 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 821333801 | CMS |
| Myovant Sciences Inc. | $12.99 | 06/02/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 834955457 | CMS |
| AstraZeneca Pharmaceuticals LP | $13.08 | 05/27/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 830061809 | CMS |
| Dendreon Pharmaceuticals LLC | $17.34 | 05/26/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 851426609 | CMS |
| Antares Pharma, Inc. | $17.45 | 05/24/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 827486209 | CMS |
| Astellas Pharma US Inc | $15.69 | 05/20/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 821333789 | CMS |
| Astellas Pharma US Inc | $2,090.00 | 05/20/2021 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 821333795 | CMS |
| TOLMAR Pharmaceuticals, Inc. | $12.03 | 05/19/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 836489329 | CMS |
| Astellas Pharma US Inc | $1,045.00 | 05/18/2021 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 821333783 | CMS |
| Bayer HealthCare Pharmaceuticals Inc. | $16.22 | 05/18/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 789086955 | CMS |
| AbbVie Inc. | $12.36 | 05/17/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 794580121 | CMS |
| Astellas Pharma US Inc | $1,045.00 | 05/17/2021 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 821333777 | CMS |
| Janssen Biotech, Inc. | $6.02 | 05/12/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 788046503 | CMS |
| Astellas Pharma US Inc | $5.11 | 05/06/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 821333770 | CMS |
| Blue Earth Diagnostics Limited | $22.79 | 05/06/2021 | Food and Beverage | No dispute reported | Delay: No Change: CHANGED | 06/30/2026 | 844623941 | CMS |
| Astellas Pharma US Inc | $13.41 | 05/03/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 821333764 | CMS |
| Janssen Biotech, Inc. | $1,000.00 | 05/03/2021 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 788046485 | CMS |
| Myovant Sciences Inc. | $25.68 | 04/30/2021 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 834955455 | CMS |
| Astellas Pharma US Inc | $2,090.00 | 04/29/2021 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 821333758 | CMS |
| Allergan, Inc. | $15.67 | 04/28/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 792781181 | CMS |
| Myovant Sciences Inc. | $2,275.00 | 04/28/2021 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 834955453 | CMS |
| Myovant Sciences Inc. | $93.17 | 04/27/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 834955451 | CMS |
| Amgen Inc. | $20.43 | 04/26/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 825546867 | CMS |
| Astellas Pharma US Inc | $22.33 | 04/21/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 821333753 | CMS |
| Teleflex LLC | $15.27 | 04/21/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 826676455 | CMS |
| Exelixis Inc. | $1,980.00 | 04/20/2021 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 838866625 | CMS |
| Dendreon Pharmaceuticals LLC | $20.55 | 04/19/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 851426607 | CMS |
| Myovant Sciences Inc. | $23.93 | 04/19/2021 | Education | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 834955449 | CMS |
| AstraZeneca Pharmaceuticals LP | $13.08 | 04/15/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 829703109 | CMS |
| Myovant Sciences Inc. | $12.20 | 04/14/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 834955447 | CMS |
| Bayer HealthCare Pharmaceuticals Inc. | $12.55 | 04/12/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 789181757 | CMS |
By program year
All program years on this page · sorted by year
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-06-30
- Program years on this page
- 2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
- Source files
- Dataset page · Bulk file · PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024 , PY2025
- Generated from
- OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.
Research Payments
One row per program year and role, newest year first · amounts for the two roles are never added together
| Program year | Role | Amount | Records |
|---|---|---|---|
| PY2025 | Principal investigator | $97,228.40 | 28 |
| PY2024 | Principal investigator | $380,223.92 | 43 |
| PY2023 | Principal investigator | $426,904.31 | 37 |
| PY2022 | Principal investigator | $637,507.29 | 81 |
| PY2021 | Principal investigator | $582,019.29 | 97 |
| PY2020 | Principal investigator | $765,957.29 | 159 |
| PY2019 | Principal investigator | $791,586.46 | 139 |
Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.
“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”
— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224
Research Payments records · PY2025
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
28 records in PY2025
| Role | Paying entity | Amount | Date | Recipient | Study | Dispute status | Published | Record ID |
|---|---|---|---|---|---|---|---|---|
| Principal investigator 1 | Janssen Research & Development, LLC | $27,750.00 | 12/23/2025 | Non-covered Recipient Entity HELIOS CR INC | A Phase 3, Randomized, Open-label, Multicenter Study Evaluating the Efficacy and Safety of TAR-210 Erdafitinib Intravesical Delivery System Versus Investigator's Choice of Intravesical Chemotherapy in Participants with High-risk Non-muscle-invasive Bladder Cancer with Susceptible FGFR Alterations Who Had Received Intravesical Bacillus Calmette-Gurin (BCG) | No dispute reported | 06/30/2026 | 1175427662 |
| Principal investigator 1 | Janssen Research & Development, LLC | $787.50 | 11/17/2025 | Non-covered Recipient Entity HELIOS CR INC | A Phase 3, Randomized, Open-label, Multicenter Study Evaluating the Efficacy and Safety of TAR-210 Erdafitinib Intravesical Delivery System Versus Investigator's Choice of Intravesical Chemotherapy in Participants with High-risk Non-muscle-invasive Bladder Cancer with Susceptible FGFR Alterations Who Had Received Intravesical Bacillus Calmette-Gurin (BCG) | No dispute reported | 06/30/2026 | 1175427565 |
| Principal investigator 1 | Janssen Research & Development, LLC | $26,000.00 | 10/30/2025 | Non-covered Recipient Entity HELIOS CR INC | A Phase 3, Randomized, Open-label, Multicenter Study Evaluating the Efficacy and Safety of TAR-210 Erdafitinib Intravesical Delivery System Versus Investigator's Choice of Intravesical Chemotherapy in Participants with High-risk Non-muscle-invasive Bladder Cancer with Susceptible FGFR Alterations Who Had Received Intravesical Bacillus Calmette-Gurin (BCG) | No dispute reported | 06/30/2026 | 1175427732 |
| Principal investigator 1 | Janssen Research & Development, LLC | $7,311.20 | 06/12/2025 | Non-covered Recipient Entity Clnc Rsrch Solutions, Llc | A Multi Center Randomized Double Blind Placebo Controlled Phase III Study of ARN509 in Men With Non Metastatic M0 Castration Resistant Prostate Cancer | No dispute reported | 06/30/2026 | 1175300954 |
| Principal investigator 1 | MEDIVATION LLC. | $697.45 | 05/21/2025 | Non-covered Recipient Entity HELIOS CLINICAL RESEARCH LLC | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228829382 |
| Principal investigator 1 | MEDIVATION LLC. | $1,245.40 | 05/21/2025 | Non-covered Recipient Entity HELIOS CLINICAL RESEARCH LLC | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228829470 |
| Principal investigator 1 | MEDIVATION LLC. | $312.00 | 05/21/2025 | Non-covered Recipient Entity HELIOS CLINICAL RESEARCH LLC | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228829491 |
| Principal investigator 1 | MEDIVATION LLC. | $312.00 | 05/21/2025 | Non-covered Recipient Entity HELIOS CLINICAL RESEARCH LLC | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228829499 |
| Principal investigator 1 | MEDIVATION LLC. | $312.00 | 05/21/2025 | Non-covered Recipient Entity HELIOS CLINICAL RESEARCH LLC | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228829734 |
| Principal investigator 1 | MEDIVATION LLC. | $312.00 | 05/21/2025 | Non-covered Recipient Entity HELIOS CLINICAL RESEARCH LLC | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228829788 |
| Principal investigator 1 | MEDIVATION LLC. | $312.00 | 05/21/2025 | Non-covered Recipient Entity HELIOS CLINICAL RESEARCH LLC | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228829827 |
| Principal investigator 1 | MEDIVATION LLC. | $1,406.60 | 05/21/2025 | Non-covered Recipient Entity HELIOS CLINICAL RESEARCH LLC | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228829832 |
| Principal investigator 1 | MEDIVATION LLC. | $1,573.00 | 05/21/2025 | Non-covered Recipient Entity HELIOS CLINICAL RESEARCH LLC | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228829837 |
| Principal investigator 1 | MEDIVATION LLC. | $312.00 | 05/21/2025 | Non-covered Recipient Entity HELIOS CLINICAL RESEARCH LLC | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228829845 |
| Principal investigator 1 | MEDIVATION LLC. | $1,406.60 | 05/21/2025 | Non-covered Recipient Entity HELIOS CLINICAL RESEARCH LLC | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228829850 |
| Principal investigator 1 | MEDIVATION LLC. | $1,406.60 | 05/21/2025 | Non-covered Recipient Entity HELIOS CLINICAL RESEARCH LLC | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228829894 |
| Principal investigator 1 | MEDIVATION LLC. | $312.00 | 05/21/2025 | Non-covered Recipient Entity HELIOS CLINICAL RESEARCH LLC | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228829964 |
| Principal investigator 1 | MEDIVATION LLC. | $1,406.60 | 05/21/2025 | Non-covered Recipient Entity HELIOS CLINICAL RESEARCH LLC | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228829972 |
| Principal investigator 1 | MEDIVATION LLC. | $312.00 | 05/21/2025 | Non-covered Recipient Entity HELIOS CLINICAL RESEARCH LLC | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228829978 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $1,500.00 | 04/04/2025 | Non-covered Recipient Entity TEXAS ARTHRITIS CENTER, PA | A Randomized 2-cohort Double-blind Placebo-controlled Phase III Study of AZD5305 in Combination with Physicians Choice New Hormonal Agents in Patients with HRRm and non-HRRm Metastatic Castration-Sensitive Prostate Cancer EvoPAR-Prostate01 | No dispute reported | 06/30/2026 | 1185537307 |
| Principal investigator 1 | MEDIVATION LLC. | $1,070.00 | 03/24/2025 | Non-covered Recipient Entity CLINICAL RESEARCH SOLUTIONS LLC | PROSPER A MULTINATIONAL PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE IN PATIENTS WITH NONMETASTATIC CASTRATIONRESISTANT PROSTATE CANCER | No dispute reported | 06/30/2026 | 1228831590 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $6,500.00 | 03/05/2025 | Non-covered Recipient Entity HELIOS CLINICAL RESEARCH INC | RELUGOLIX VERSUS LEUPROLIDE IN PATIENTS WITH PROSTATE CANCER: A RANDOMIZED, OPEN-LABEL STUDY TO ASSESS MAJOR ADVERSE CARDIOVASCULAR EVENTS (REPLACE-CV) | No dispute reported | 06/30/2026 | 1176630235 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $5,000.00 | 03/05/2025 | Non-covered Recipient Entity HELIOS CLINICAL RESEARCH INC | RELUGOLIX VERSUS LEUPROLIDE IN PATIENTS WITH PROSTATE CANCER: A RANDOMIZED, OPEN-LABEL STUDY TO ASSESS MAJOR ADVERSE CARDIOVASCULAR EVENTS (REPLACE-CV) | No dispute reported | 06/30/2026 | 1176630239 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $1,500.00 | 03/05/2025 | Non-covered Recipient Entity HELIOS CLINICAL RESEARCH INC | RELUGOLIX VERSUS LEUPROLIDE IN PATIENTS WITH PROSTATE CANCER: A RANDOMIZED, OPEN-LABEL STUDY TO ASSESS MAJOR ADVERSE CARDIOVASCULAR EVENTS (REPLACE-CV) | No dispute reported | 06/30/2026 | 1176630242 |
| Principal investigator 1 | MEDIVATION LLC. | $312.00 | 03/03/2025 | Non-covered Recipient Entity CLINICAL RESEARCH SOLUTIONS LLC | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228832073 |
| Principal investigator 1 | MEDIVATION LLC. | $697.45 | 03/03/2025 | Non-covered Recipient Entity CLINICAL RESEARCH SOLUTIONS LLC | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228832250 |
| Principal investigator 1 | MEDIVATION LLC. | $312.00 | 03/03/2025 | Non-covered Recipient Entity CLINICAL RESEARCH SOLUTIONS LLC | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228832255 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $6,850.00 | 02/05/2025 | Non-covered Recipient Entity HELIOS CLINICAL RESEARCH | A Randomized 2-cohort Double-blind Placebo-controlled Phase III Study of AZD5305 in Combination with Physicians Choice New Hormonal Agents in Patients with HRRm and non-HRRm Metastatic Castration-Sensitive Prostate Cancer EvoPAR-Prostate01 | No dispute reported | 06/30/2026 | 1185537305 |